JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.65 2.82

Buy Sell

Overview

Share price change

24h

Current

Min

3.65

Max

3.7

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+258.7% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-32M 222M
Previous open	0.83
Previous close	3.65

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 lut 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 lut 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 lut 2026, 02:46 UTC

Acquisitions, Mergers, Takeovers

Big Money, High Anxiety -- Barrons.com

6 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6 lut 2026, 21:40 UTC

Acquisitions, Mergers, Takeovers

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 lut 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 lut 2026, 21:17 UTC

Earnings

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 lut 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 lut 2026, 21:14 UTC

Acquisitions, Mergers, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 lut 2026, 21:13 UTC

Earnings

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 lut 2026, 21:13 UTC

Earnings

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 lut 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 lut 2026, 20:34 UTC

Earnings

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 lut 2026, 20:27 UTC

Earnings

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 lut 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 lut 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 lut 2026, 19:48 UTC

Earnings

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 lut 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 lut 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 lut 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 lut 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 lut 2026, 18:50 UTC

Earnings

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 lut 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 lut 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 lut 2026, 17:58 UTC

Earnings

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 lut 2026, 17:52 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

6 lut 2026, 17:52 UTC

Market Talk

Earnings

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 lut 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

258.7% upside

12 Months Forecast

Average 13.2 USD 258.7%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.